Sarah Woolnough

For years the respiratory life sciences have been underfunded, despite lung conditions affecting one in five people in the UK and being the third biggest cause of death. Our CEO, Sarah Woolnough explains what we believe needs to change and our ideas for improving research and innovation in lung health.